Loading stock data…
Annovis Bio (ANVS)
$1.84+0.13 (+7.27%)
Market OpenUpdated 2:09 PM EDT
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Annovis Bio, Inc. in the Healthcare sector is trading at $1.77 with a market capitalization of $76M. Wall Street consensus targets $12.50 (2 analysts), implying a +606.2% move over the next 12 months. The stock is currently near its 52-week low of $1.54, remaining 30.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +606.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$18.01M↓ | -$9.71M↓ | -$7.43M↓ | -$6.27M↑ | -$6.28M |
| Net Income | -$17.61M↓ | -$9.83M↓ | -$7.26M↓ | -$6.22M↓ | -$5.54M |
Peer Comparison
JNJUNHPFE
Fundamentals
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$76.15M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1309.11%
Volume
Today's trading volume
522,239
Recent News
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced
Most biotech stocks working towards a treatment for Parkinson's are already carrying a premium price. These three sit further off the radar, and analysts think the market has them badly wrong.
Annovis (ANVS) Secures Patent Coverage for Both Forms of Buntanetap
Annovis Bio, Inc. (NYSE:ANVS) is one of the best meme stocks. On August 7, Annovis announced that it has finished transferring patents for both the older semi-crystalline and the newer crystalline versions of its drug candidate, buntanetap. These patents will now protect the drug until 2046. The company, which works on drugs for brain-related diseases, […]